Inspectors found black mold at a Chinese plant supplying compounded GLP-1 ingredients
The Briefing, October 18, 2026. This week in peptides, in plain English.
Vol. 1 · Issue 04October 18, 2026
FDA inspection files describe contamination at plants feeding compounded semaglutide and tirzepatide, plus new trials in runners and in sepsis.
Safety · Lead
FDA inspection files describe black mold at a plant making ingredients for compounded semaglutide and tirzepatide
FDA inspection reports, obtained by Bloomberg through a Freedom of Information Act request and reported on 15 October, describe black mold on equipment and gross contamination at a Chinese factory that makes ingredients for compounded semaglutide and tirzepatide. Inspectors also caught staff hiding paperwork and pouring out samples. At a second plant, they found evidence of fake documents.
Why this matters for a reader: compounded versions of these drugs are made by pharmacies from bulk active ingredients that are manufactured elsewhere, and these reports concern that upstream step. A finished product depends on the quality of what goes into it. Contamination on equipment and signs of concealed or falsified records are exactly the kinds of problems inspections exist to catch.
What it does not mean: the reports, as summarised, cover specific plants. They do not on their own show which compounded products, if any, were made from these batches or reached patients, and they are not evidence that every compounded semaglutide or tirzepatide product is contaminated. The summary we have also does not describe what regulatory action, if any, followed.
The broader point is that the same molecule name does not guarantee the same manufacturing standard. For background on how these drugs work and their approved forms, see the semaglutide and tirzepatide dossiers.
Two new trials will test semaglutide in well-trained runners
Two randomized, placebo-controlled studies registered on ClinicalTrials.gov on 15 October will look at what semaglutide does to lean, fit athletes. One focuses on short-term effects, the other on long-term effects. Both will enrol well-trained male and female runners and measure body composition, muscle mass, muscle volume and function, running economy and performance. The long-term study adds hormonal markers.
The registrations state the gap plainly: semaglutide has shown significant weight-loss effects in people with obesity or type 2 diabetes, but its impact on exercise performance in lean, fit athletes is unknown. The focus on muscle mass and function suggests the researchers want to know what happens to muscle, not just weight, when people who are not overweight take the drug.
What it does not mean: neither study has started recruiting, so there are no results. Nothing here suggests semaglutide improves athletic performance; that is one of the open questions the studies are designed to answer, and the answer could go either way.
Placebo control is a strength of the design, since performance measures are easily nudged by expectation. The semaglutide dossier covers what is already established in its approved uses.
A small trial in China tests thymosin alpha-1 for immune recovery in sepsis
A trial registered on 8 October and now recruiting at Zhongshan Hospital, Fudan University, will test whether adding thymalfasin, also called thymosin alpha-1, to usual sepsis care helps immune function recover. It will enrol 60 adults with sepsis who show signs of reduced immune function, split by chance into two groups of 30: usual care plus thymalfasin injections for 7 days, or usual care alone.
The main outcome is a blood marker, the change in monocyte HLA-DR expression between the start and day 7, which reflects how well immune cells are working. The researchers will also track immune cells, organ function, organ support, infections, survival and safety, with follow-up to day 90.
How to read it: this is a small study, and there is no placebo, so patients and treating clinicians will know who received the drug. Laboratory staff measuring the immune outcomes will not know the assignments, which helps protect the main measurement. A positive result on a blood marker would not by itself show that patients recover better or survive more often.
For a reader, this is a sign that thymosin alpha-1 is still being studied in serious hospital illness, not evidence of benefit yet. The dossier page has more on what the peptide is and how it is thought to work.
GHK-Cu side effects: why the sting is expected, and what people say helps
GHK-Cu is a naturally occurring copper-binding peptide. It delivers copper to tissues and switches on genes involved in repair, and it is studied for collagen and elastin production, wound healing, skin aging and hair density. Natural levels fall sharply between your twenties and sixties, which is part of why it attracts interest.
The side effect people report most is local. When injected, GHK-Cu stings more than most peptides, and irritation, redness and swelling at the injection site are expected rather than unusual. If you read accounts of people using it, this is the complaint that comes up again and again.
What helps, according to the reference notes: a more dilute, less concentrated solution, rotating injection sites so the same patch of skin is not used repeatedly, and brief icing. These are comfort measures, not fixes for anything more serious. Irritation that goes beyond the expected is a reason to talk to a doctor.
There is one firm caution. Because GHK-Cu delivers copper, anyone with Wilson's disease or another copper disorder should not use it without a doctor's involvement.
Keep the evidence in proportion. GHK-Cu has strong lab evidence and decades of use in topical cosmetics, but human data on injecting it is limited. It is widely used in creams and serums and is not FDA-approved as an injectable. The GHK-Cu dossier at jointhedailystack.com/peptides/ghk-cu/ has the full detail.